Trial intelligence / Profile preview

ATOMIC: adjuvant mFOLFOX6 with or without atezolizumab for stage III dMMR colon cancer

2024-517269-18-00Phase 3Authorised

Sponsor: AIO-Studien-gGmbH
Start: Sep 2024
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Countries: 2

Overview

Phase 3, randomised, open-label trial of atezolizumab in colon adenocarcinoma (2 arms), sponsored by AIO-Studien-gGmbH. Primary endpoint: Disease-free survival. Planned start Sep 2024; status: authorised.

Drugs

atezolizumab

Conditions

colon adenocarcinoma

Beyond the preview

Go deeper on 2024-517269-18-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-517269-18-00.